Moleculin Biotech面临收入释放、预期损失和“销售”分析师评级。 Moleculin Biotech faces earnings release, predicted loss, and a "sell" analyst rating.

Moleculin Biotech (MBRX)定于3月21日释放季度收入, 分析家预测每股损失1. 25美元。 Moleculin Biotech (MBRX) is set to release its quarterly earnings on March 21st, with analysts predicting a loss of $1.25 per share. 股票升至1.09美元,交易额为451 309股。 The stock rose to $1.09, trading at a volume of 451,309 shares. 分析师已经把股票降为"销售"评级 Analysts have downgraded the stock to a "sell" rating. Moleculin生物科技侧重于发展癌症和病毒治疗,其主要药物是Annamycin,用于治疗AML和Sarcoma的临床试验。 Moleculin Biotech focuses on developing cancer and virus treatments, with its lead drug, Annamycin, in clinical trials for treating AML and sarcoma.